Intestinal absorption of BCS class II drugs administered as nanoparticles: A review based on in vivo data from intestinal perfusion models
An established pharmaceutical strategy to increase oral drug absorption of low solubility–high permeability drugs is to create nanoparticles of them. Reducing the size of the solid-state particles increases their dissolution and transport rate across the mucus barrier and the aqueous boundary layer...
Main Authors: | David Dahlgren, Erik Sjögren, Hans Lennernäs |
---|---|
Format: | Article |
Language: | English |
Published: |
International Association of Physical Chemists (IAPC)
2020-09-01
|
Series: | ADMET and DMPK |
Online Access: | https://pub.iapchem.org/ojs/index.php/admet/article/view/881 |
Similar Items
-
Intestinal Permeability and Drug Absorption: Predictive Experimental, Computational and In Vivo Approaches
by: David Dahlgren, et al.
Published: (2019-08-01) -
BCS Class IV Oral Drugs and Absorption Windows: Regional-Dependent Intestinal Permeability of Furosemide
by: Milica Markovic, et al.
Published: (2020-12-01) -
The In Vivo Effect of Transcellular Permeation Enhancers on the Intestinal Permeability of Two Peptide Drugs Enalaprilat and Hexarelin
by: David Dahlgren, et al.
Published: (2020-01-01) -
On Absorption Modeling and Food Effect Prediction of Rivaroxaban, a BCS II Drug Orally Administered as an Immediate-Release Tablet
by: Varun Kushwah, et al.
Published: (2021-02-01) -
Lipid nanoparticles: A challenging approach for oral delivery of BCS Class-II drugs
by: Ganesan Poovi, et al.
Published: (2018-12-01)